



## Sporanox<sup>®</sup> (itraconazole) – First-time generic

- On September 19, 2018, Amneal Pharmaceuticals launched an [AA-rated](#) generic version of [Sporanox \(itraconazole\)](#) oral solution.
- Sporanox oral solution is indicated for the treatment of oropharyngeal and esophageal candidiasis.
- Sporanox is also available generically as an oral [capsule](#), which is approved for the treatment of:
  - Blastomycosis, histoplasmosis, and aspergillosis in immunocompromised and non-immunocompromised patients
  - Onychomycosis of the toenail or fingernail in non-immunocompromised patients.
- Sporanox carries a boxed warning for congestive heart failure, cardiac effects, and drug interactions.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.